S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   290.93 (-4.98%)
AAPL   140.65 (-5.76%)
MSFT   254.13 (-4.76%)
FB   192.54 (-4.97%)
GOOGL   2,242.68 (-3.73%)
AMZN   2,139.15 (-7.29%)
TSLA   708.27 (-7.00%)
NVDA   169.86 (-6.55%)
BABA   87.41 (-4.98%)
NIO   15.80 (-4.99%)
AMD   96.59 (-5.74%)
CGC   5.59 (-5.09%)
MU   71.28 (-4.30%)
T   20.17 (-1.94%)
GE   75.06 (-1.75%)
F   12.75 (-5.76%)
DIS   104.21 (-4.08%)
AMC   12.70 (-1.55%)
PFE   50.34 (-1.95%)
PYPL   77.21 (-3.18%)
NFLX   177.25 (-6.98%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   290.93 (-4.98%)
AAPL   140.65 (-5.76%)
MSFT   254.13 (-4.76%)
FB   192.54 (-4.97%)
GOOGL   2,242.68 (-3.73%)
AMZN   2,139.15 (-7.29%)
TSLA   708.27 (-7.00%)
NVDA   169.86 (-6.55%)
BABA   87.41 (-4.98%)
NIO   15.80 (-4.99%)
AMD   96.59 (-5.74%)
CGC   5.59 (-5.09%)
MU   71.28 (-4.30%)
T   20.17 (-1.94%)
GE   75.06 (-1.75%)
F   12.75 (-5.76%)
DIS   104.21 (-4.08%)
AMC   12.70 (-1.55%)
PFE   50.34 (-1.95%)
PYPL   77.21 (-3.18%)
NFLX   177.25 (-6.98%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   290.93 (-4.98%)
AAPL   140.65 (-5.76%)
MSFT   254.13 (-4.76%)
FB   192.54 (-4.97%)
GOOGL   2,242.68 (-3.73%)
AMZN   2,139.15 (-7.29%)
TSLA   708.27 (-7.00%)
NVDA   169.86 (-6.55%)
BABA   87.41 (-4.98%)
NIO   15.80 (-4.99%)
AMD   96.59 (-5.74%)
CGC   5.59 (-5.09%)
MU   71.28 (-4.30%)
T   20.17 (-1.94%)
GE   75.06 (-1.75%)
F   12.75 (-5.76%)
DIS   104.21 (-4.08%)
AMC   12.70 (-1.55%)
PFE   50.34 (-1.95%)
PYPL   77.21 (-3.18%)
NFLX   177.25 (-6.98%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   290.93 (-4.98%)
AAPL   140.65 (-5.76%)
MSFT   254.13 (-4.76%)
FB   192.54 (-4.97%)
GOOGL   2,242.68 (-3.73%)
AMZN   2,139.15 (-7.29%)
TSLA   708.27 (-7.00%)
NVDA   169.86 (-6.55%)
BABA   87.41 (-4.98%)
NIO   15.80 (-4.99%)
AMD   96.59 (-5.74%)
CGC   5.59 (-5.09%)
MU   71.28 (-4.30%)
T   20.17 (-1.94%)
GE   75.06 (-1.75%)
F   12.75 (-5.76%)
DIS   104.21 (-4.08%)
AMC   12.70 (-1.55%)
PFE   50.34 (-1.95%)
PYPL   77.21 (-3.18%)
NFLX   177.25 (-6.98%)
NASDAQ:ALKS

Alkermes (ALKS) Stock Forecast, Price & News

$28.80
-0.89 (-3.00%)
(As of 05/18/2022 03:52 PM ET)
Add
Compare
Today's Range
$28.66
$29.63
50-Day Range
$23.57
$30.38
52-Week Range
$21.24
$33.00
Volume
52,302 shs
Average Volume
2.00 million shs
Market Capitalization
$4.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.75
30 days | 90 days | 365 days | Advanced Chart
Receive ALKS News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

Alkermes logo

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALKS
CUSIP
G0176710
Employees
2,211
Year Founded
1987

Sales & Book Value

Annual Sales
$1.17 billion
Cash Flow
$0.79 per share
Book Value
$6.88 per share

Profitability

Net Income
$-48.17 million
Pretax Margin
-5.47%

Debt

Price-To-Earnings

Miscellaneous

Free Float
155,860,000
Market Cap
$4.71 billion
Optionable
Optionable

Company Calendar

Last Earnings
4/27/2022
Today
5/18/2022
Next Earnings (Estimated)
7/27/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

1.68 out of 5 stars

Medical Sector

916th out of 1,426 stocks

Pharmaceutical Preparations Industry

456th out of 680 stocks

Analyst Opinion: 1.1Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -













Alkermes (NASDAQ:ALKS) Frequently Asked Questions

Is Alkermes a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Alkermes stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALKS, but not buy additional shares or sell existing shares.
View analyst ratings for Alkermes
or view top-rated stocks.

When is Alkermes' next earnings date?

Alkermes is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Alkermes
.

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) posted its earnings results on Wednesday, April, 27th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.11. The firm had revenue of $278.55 million for the quarter, compared to analyst estimates of $256.02 million. Alkermes had a negative net margin of 5.13% and a positive trailing twelve-month return on equity of 3.87%. The company's quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.01 EPS.
View Alkermes' earnings history
.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes issued an update on its FY22 earnings guidance on Wednesday, April, 27th. The company provided earnings per share (EPS) guidance of $(0.18)-0.00 for the period, compared to the consensus EPS estimate of ($0.10). The company issued revenue guidance of $1.00-1.09 billion, compared to the consensus revenue estimate of $1.05 billion.

What price target have analysts set for ALKS?

9 brokerages have issued 1-year price objectives for Alkermes' shares. Their forecasts range from $25.00 to $36.00. On average, they anticipate Alkermes' stock price to reach $30.67 in the next twelve months. This suggests a possible upside of 6.5% from the stock's current price.
View analysts' price targets for Alkermes
or view top-rated stocks among Wall Street analysts.

Who are Alkermes' key executives?
Alkermes' management team includes the following people:
What is Richard F. Pops' approval rating as Alkermes' CEO?

119 employees have rated Alkermes CEO Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among Alkermes' employees.

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), (CELG), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Who are Alkermes' major shareholders?

Alkermes' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.28%), BlackRock Inc. (9.23%), Wellington Management Group LLP (7.02%), State Street Corp (3.54%), Primecap Management Co. CA (3.47%) and Hardman Johnston Global Advisors LLC (3.22%). Company insiders that own Alkermes stock include Blair Curtis Jackson, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Richard F Pops, Shane Cooke and Wendy L Dixon.
View institutional ownership trends for Alkermes
.

Which institutional investors are selling Alkermes stock?

ALKS stock was sold by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Federated Hermes Inc., Wellington Management Group LLP, Bank of New York Mellon Corp, Woodline Partners LP, Hardman Johnston Global Advisors LLC, Russell Investments Group Ltd., and Edgestream Partners L.P.. Company insiders that have sold Alkermes company stock in the last year include Blair Curtis Jackson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Michael J Landine, Richard F Pops, Shane Cooke, and Wendy L Dixon.
View insider buying and selling activity for Alkermes
or view top insider-selling stocks.

Which institutional investors are buying Alkermes stock?

ALKS stock was bought by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, BlackRock Inc., Teacher Retirement System of Texas, Eagle Asset Management Inc., Goldman Sachs Group Inc., Integral Health Asset Management LLC, JPMorgan Chase & Co., and State Street Corp.
View insider buying and selling activity for Alkermes
or or view top insider-buying stocks.

How do I buy shares of Alkermes?

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $28.80.

How much money does Alkermes make?

Alkermes has a market capitalization of $4.71 billion and generates $1.17 billion in revenue each year. The company earns $-48.17 million in net income (profit) each year or ($0.38) on an earnings per share basis.

How many employees does Alkermes have?

Alkermes employs 2,211 workers across the globe.

Does Alkermes have any subsidiaries?

The following companies are subsidiares of Alkermes: Rodin Therapeutics.

When was Alkermes founded?

Alkermes was founded in 1987.

What is Alkermes' official website?

The official website for Alkermes is www.alkermes.com.

How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at (531) 772-8000, via email at [email protected], or via fax at 781-890-0524.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.